158 related articles for article (PubMed ID: 38420885)
1. Access to MAT: Participants' Experiences With Transportation, Non-Emergency Transportation, and Telehealth.
Boyd J; Carter M; Baus A
J Prim Care Community Health; 2024; 15():21501319241233198. PubMed ID: 38420885
[TBL] [Abstract][Full Text] [Related]
2. Medication Assisted Treatment Program Policies: Opinions of People in Treatment.
Carter M; Boyd J; Bennett T; Baus A
J Prim Care Community Health; 2023; 14():21501319231195606. PubMed ID: 37635696
[TBL] [Abstract][Full Text] [Related]
3. Perceived Ability to Treat Opioid Use Disorder in West Virginia.
Sheppard AB; Young JC; Davis SM; Moran GE
J Appalach Health; 2021; 3(2):32-42. PubMed ID: 35769171
[TBL] [Abstract][Full Text] [Related]
4. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
[TBL] [Abstract][Full Text] [Related]
5. A Better Life: Factors that Help and Hinder Entry and Retention in MAT from the Perspective of People in Recovery.
Baus AD; Carter M; Boyd J; McMullen E; Bennett T; Persily A; Davidov DM; Lilly C
J Appalach Health; 2023; 5(1):72-94. PubMed ID: 38023116
[TBL] [Abstract][Full Text] [Related]
6. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
[TBL] [Abstract][Full Text] [Related]
7. Patient Perceptions of Video Visits Using Veterans Affairs Telehealth Tablets: Survey Study.
Slightam C; Gregory AJ; Hu J; Jacobs J; Gurmessa T; Kimerling R; Blonigen D; Zulman DM
J Med Internet Res; 2020 Apr; 22(4):e15682. PubMed ID: 32293573
[TBL] [Abstract][Full Text] [Related]
8. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.
Bailey SR; Wyte-Lake T; Lucas JA; Williams S; Cantone RE; Garvey BT; Hallock-Koppelman L; Angier H; Cohen DJ
Subst Use Misuse; 2023; 58(9):1143-1151. PubMed ID: 37170596
[No Abstract] [Full Text] [Related]
9. Essential not Supplemental: Medicare Advantage Members' Use of Non-Emergency Medical Transportation (NEMT).
Razon N; Gottlieb LM; Fraze T
J Gen Intern Med; 2023 Dec; 38(16):3566-3573. PubMed ID: 37464149
[TBL] [Abstract][Full Text] [Related]
10. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
Yeo EJ; Kralles H; Sternberg D; McCullough D; Nadanasabesan A; Mayo R; Akselrod H; Catalanotti J
Harm Reduct J; 2021 Dec; 18(1):127. PubMed ID: 34886850
[TBL] [Abstract][Full Text] [Related]
11. How Does Telehealth Expansion Change Access to Healthcare for Patients With Different Types of Substance Use Disorders?
Tilhou AS; Burns M; Chachlani P; Chen Y; Dague L
Subst Use Addctn J; 2024 Jul; 45(3):473-485. PubMed ID: 38494728
[TBL] [Abstract][Full Text] [Related]
12. Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.
Cochran G; Cole ES; Warwick J; Donohue JM; Gordon AJ; Gellad WF; Bear T; Kelley D; DiDomenico E; Pringle J
Addict Sci Clin Pract; 2019 Aug; 14(1):25. PubMed ID: 31366408
[TBL] [Abstract][Full Text] [Related]
13. People's Experiences and Satisfaction With Telehealth During the COVID-19 Pandemic in Australia: Cross-Sectional Survey Study.
Isautier JM; Copp T; Ayre J; Cvejic E; Meyerowitz-Katz G; Batcup C; Bonner C; Dodd R; Nickel B; Pickles K; Cornell S; Dakin T; McCaffery KJ
J Med Internet Res; 2020 Dec; 22(12):e24531. PubMed ID: 33156806
[TBL] [Abstract][Full Text] [Related]
14. Patients' and Clinicians' Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study.
Wyte-Lake T; Cohen DJ; Williams S; Casey D; Chan M; Frank B; Levander XA; Stein D; White KK; Bailey SR
J Gen Intern Med; 2024 Jan; ():. PubMed ID: 38228990
[TBL] [Abstract][Full Text] [Related]
15. Telehealth to improve continuity for patients receiving buprenorphine treatment for opioid use disorder.
Sahu N; Chen PH; Shimoni N
Ann Fam Med; 2022 Apr; 20(20 Suppl 1):. PubMed ID: 35947491
[TBL] [Abstract][Full Text] [Related]
16. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
Cales RH; Cales SC; Shreffler J; Huecker MR
J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
[TBL] [Abstract][Full Text] [Related]
17. Review of medication-assisted treatment for opioid use disorder.
Ghanem N; Dromgoole D; Hussein A; Jermyn RT
J Osteopath Med; 2022 Mar; 122(7):367-374. PubMed ID: 35285220
[TBL] [Abstract][Full Text] [Related]
18. Rideshare transportation to health care: evidence from a Medicaid implementation.
Eisenberg Y; Owen R; Crabb C; Morales M
Am J Manag Care; 2020 Sep; 26(9):e276-e281. PubMed ID: 32930556
[TBL] [Abstract][Full Text] [Related]
19. Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.
Ferries E; Racsa P; Bizzell B; Rhodes C; Suehs B
J Manag Care Spec Pharm; 2021 May; 27(5):596-606. PubMed ID: 33908274
[No Abstract] [Full Text] [Related]
20. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
